Treatment of dyslipidemia in the older adult
- Robert S Rosenson, MD
Robert S Rosenson, MD
- Section Editor — Lipids
- Professor of Medicine
- Mount Sinai School of Medicine
- Director, Cardiometabolic Disorders
- Mount Sinai Heart
- Section Editors
- Mason W Freeman, MD
Mason W Freeman, MD
- Section Editor — Lipids
- Professor of Medicine
- Harvard Medical School
- Kenneth E Schmader, MD
Kenneth E Schmader, MD
- Editor in Chief — Geriatric Medicine
- Section Editor — Geriatrics
- Chief, Division of Geriatrics
- Duke University
- Director, Geriatric Research Education and Clinical Center
- Durham VA Medical Centers
Clinical trials of cholesterol lowering therapies have demonstrated consistent near-term benefits for patients with established coronary heart disease (CHD) and long-term benefits for those with severe hypercholesterolemia who are currently free of clinical CHD (see "Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease"). Unfortunately, these trials have typically excluded older patients.
The bias against older individuals stems from illusory concerns regarding life expectancy, comorbidity, safety of lipid lowering agents, and cost-benefit analysis of preventive care in older adults. In fact, the absolute risk for CHD increases dramatically with age in both men and women (figure 1). Thus, the absolute number of persons benefiting from cholesterol lowering should be greater in older adults [1,2].
CARDIOVASCULAR DISEASE IN OLDER ADULTS
A large proportion of older individuals will suffer from coronary heart disease (CHD). In men over the age of 65, for example, nearly one-half of all deaths are attributed to CHD, compared to less than 25 percent for all cancers and less than 2 percent for all infections. An even higher proportion of deaths are due to CHD in older women (56 percent) with less than 20 percent being due to cancer.
Age-related changes in lipoprotein metabolism — Longitudinal studies have shown that total cholesterol levels increase in males after the onset of puberty until age 50. This is followed by a plateau until age 70, with the serum cholesterol concentration then falling slightly. Although it has been suspected that the latter change may be an artifact resulting from CHD deaths in hypercholesterolemic men , the most important factor influencing cholesterol may be weight change . The reduction in total and LDL cholesterol and the increase in HDL-cholesterol in older men, primarily occur in those who lost weight, while age is not a factor.
In women, the serum cholesterol concentration is slightly higher than in men prior to age 20 to 25. Between the ages of 25 to 55, the serum cholesterol rises although at a slower incremental rate than in men. Cholesterol levels in women are equal to those of men between the ages of 55 to 60 and exceed those in men in older age groups.
Subscribers log in hereLiterature review current through: Jul 2017. | This topic last updated: Feb 23, 2016.References
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.
- Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159:1670.
- Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987; 82:54.
- Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997; 96:37.
- Ericsson S, Eriksson M, Vitols S, et al. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991; 87:591.
- Castelli WP, Wilson PW, Levy D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63:12H.
- Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990; 263:393.
- Agner E, Hansen PF. Fasting serum cholesterol and triglycerides in a ten-year prospective study in old age. Acta Med Scand 1983; 214:33.
- Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113:916.
- Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996; 94:2381.
- Houterman S, Verschuren WM, Hofman A, Witteman JC. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med 1999; 246:25.
- Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274:539.
- Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126:753.
- Malenka DJ, Baron JA. Cholesterol and coronary heart disease. The importance of patient-specific attributable risk. Arch Intern Med 1988; 148:2247.
- Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96:4211.
- Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.
- Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129:681.
- LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation 2001; 104:1688.
- Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134:931.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.
- Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29:2378.
- Wenger NK, Lewis SJ, Herrington DM, et al. Effect of 80 mg versus 10 mg of atorvastatin in patients ≥ and <65 years of age with stable coronary heart disease. Circulation 2005; 112:II.
- Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147:1.
- Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893.
- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.
- Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.
- Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010; 152:488.
- Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40:1777.
- Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623.
- Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115:700.
- Wenger NK. Personal communication (July 9, 2007).
- Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2013; 62:2090.
- Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455.
- Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.
- Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.
- Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129.
- Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104:376.
- LaRosa JC, Applegate W, Crouse JR 3rd, et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154:529.
- Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994; 96:509.
- Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 2014; 312:1136.
- Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162:1395.
- Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med 2015; 162:533.
- Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. Am J Cardiol 1998; 82:668.
- Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864.
- CARDIOVASCULAR DISEASE IN OLDER ADULTS
- Age-related changes in lipoprotein metabolism
- Cholesterol as a predictor of cardiovascular risk
- Relative risk versus absolute risk
- BENEFITS OF LIPID LOWERING IN OLDER ADULTS
- Clinical trials
- Time course for CHD benefit
- Side effects
- ADDITIONAL ISSUES IN OLDER ADULTS
- Secondary causes
- Dietary modifications
- Drug interactions and side effects
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS